Abandoned. By the Side of the Road. In the Rain | GenomeWeb

The US National Institutes of Health has made a deal with Pfizer, AstraZeneca, and Eli Lilly to share "abandoned experimental drugs" with academic researchers, reports ScienceInsider's Jocelyn Kaiser. The hope, Kaiser says, is that researchers will be able to find new uses for the drugs. The companies will grant access to two dozen compounds that have passed safety studies, but were deemed ineffective for a specific purpose.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.